The serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins
|
|
- Neil Fisher
- 5 years ago
- Views:
Transcription
1 Original Article Obstet Gynecol Sci 2018;61(2): pissn eissn The serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins Yoo Jin Shim 1, Aeran Seol 1, Dayong Lee 2,3, Seul Ki Kim 2,3, Jung Ryeol Lee 2,3, Byung Chul Jee 2,3, Chang Suk Suh 1,3, Seok Hyun Kim 1,3 Department of Obstetrics and Gynecology, 1 Seoul National University Hospital, Seoul, 2 Seoul National University Bundang Hospital, Seongnam, 3 Seoul National University College of Medicine, Seoul, Korea Objective To investigate the patterns of estradiol-oocyte ratio (EOR) and estradiol-mature oocyte ratio (EMOR) in patients with breast cancer undergoing controlled ovarian stimulation (COS) using letrozole and gonadotropins for fertility preservation. Methods This retrospective study included 32 breast cancer patients underwent COS for fertility preservation and no patients had previously undergone gonadotoxic treatments. Basal characteristics and in vitro fertilization (IVF) outcomes were compared according to the age of women (age <35 vs. age 35) and the starting phase of ovarian stimulation (early follicular phase vs. late follicular phase vs. luteal phase). Results Patients who were administered with a letrozole-combined regimen, the peak serum estradiol (E2) was maintained at a low level (386.3±346.9 pg/ml). EOR was 52.4±78.8 pg/ml, and EMOR was 71.0±41.2 pg/ml. When the 2 groups were compared according to the age of women (age <35 vs. age 35), EOR was 34.5 ( ) pg/ml and 40.7 ( ) pg/ml, respectively; EMOR was 79.8 ( ) pg/ml and 68.8 ( ) pg/ml, respectively. There was no significant difference in the IVF outcomes. When the 2 groups were compared according to the starting phase of ovarian stimulation, there were no significant differences in IVF outcomes, EOR and EMOR among the groups. Conclusion Measuring the peak E2 concentration in breast cancer patients undergoing IVF for fertility preservation with a cotreatment of letrozole allows for the prediction of the numbers of oocytes and mature oocytes. Keywords: Breast neoplasms; Fertility preservation; Aromatase inhibitors; Estradiol; In vitro fertilization Introduction The intensity of ovarian reactivity to controlled ovarian stimulation (COS) is assessed on the basis of serum estradiol (E2) level and follicular diameter, as measured by an ultrasound. It is common to continuously administer gonadotropin until at least 2 follicles reach a mean diameter of mm and additional ovarian follicles are mm in diameter and until the serum E2 level reflects the overall size and maturity of the ovarian follicles. Follicles with a size of more than 14 mm has a serum E2 concentration of approximately 200 pg/ml Received: Revised: Accepted: Corresponding author: Seul Ki Kim Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, 82 Gumi-ro 173-beon-gil, Bundanggu, Seongnam 13620, Korea skkim@snubh.org Articles published in Obstet Gynecol Sci are open-access, distributed under the terms of the Creative Commons Attribution Non-Commercial License ( org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright 2018 Korean Society of Obstetrics and Gynecology 242
2 Yoo Jin Shim, et al. The serum estradiol/oocyte ratio [1]. Therefore, checking the serum E2 level on triggering day helps to predict the number of oocytes retrieved. During COS for in vitro fertilization (IVF), it is concerning that the serum E2 level may increase to the supraphysiologic level, since such an increase would negatively affect estrogen-dependent cancer, such as breast cancer. For this reason, gonadotropin and aromatase inhibitor (AI) are administered simultaneously to suppress an increase in the E2 level during the course of IVF [2]. AI prevents estrogen production by competitive, reversible binding of AI to the heme of cytochrome P450 unit of aromatase. Tamoxifen or AI is commonly used because they are relatively safe. Azim et al. [3] demonstrated there was no positive correlation between the number of oocytes retrieved and recurrence rate in breast cancer. There have been studies measuring the total serum E2 in letrozole co-treatment cycles [4]. These studies have shown that an administration of letrozole keeps the E2 concentration low in breast cancer patients during the course of COS. Nevertheless, there has been a paucity of data analyzing relationship between E2 concentration and IVF outcomes. Therefore, the number of oocytes retrieved prior to ovum pick up in letrozole co-treatment cycles was hard to predict. For the group with letrozole-combined administration, analyzing estradiol-oocyte ratio (EOR) will help predict the number of oocytes retrieved and IVF outcomes. The aim of this study was to investigate the patterns of EOR and estradiol-mature oocyte ratio (EMOR) in patients with breast cancer undergoing COS using letrozole and gonadotropins for fertility preservation. Materials and methods 1. Study subjects and design This retrospective study included breast cancer patients undergoing an IVF for fertility preservation between September 2012 and February 2017 in our institution. During the study period, 37 women underwent COS for fertility preservation and no patients had previously undergone gonadotoxic treatments. The exclusion criteria were as follows: patients with known poor ovarian response (POR) according to the Bologna criteria, polycystic ovarian syndrome (PCOS) according to the Rotterdam criteria, endometriosis, or other medical disorders that could potentially affect folliculogenesis. This study was approved by the Institutional Review Board of Seoul National University Bundang Hospital (B ). 2. Clinical management of cancer patients for fertility preservation All patients were evaluated for infertility risk, based on their age and gonadotoxic treatment regimen. They were counseled by an attending reproductive endocrinologist regarding various fertility preserving strategies. Pelvis ultrasound and hormonal profiles, including follicle-stimulating hormone (FSH), luteinizing hormone, E2, progesterone (P4), and anti- Mullerian hormone (AMH) were evaluated. The menstrual cycle phase was evaluated based on the onset of the last menstrual period, ultrasonographic findings, and serum P4 concentration. The early follicular phase was defined as within the first 5 days of the menstrual cycle, and the late follicular phase was defined as the period of menstrual cycle after the first 5 days with the emergence of a dominant follicle and a serum P4 level of <3 ng/ml. The luteal phase was determined by a serum P4 level of 3 ng/ml. In these patients, ovarian stimulation was started immediately, irrespective of their menstrual cycle date, without awaiting menstruation. 3. COS protocols After the baseline pelvic ultrasound and hormonal evaluation, ovarian stimulation with gonadotropin-releasing hormone (GnRH) antagonist protocol was started with recombinant FSH (Gonal-F; Serono, Geneva, Switzerland). The initial dose of gonadotropins was determined based on age and an assessment of ovarian reserve, as estimated by antral follicle count (AFC) and/or AMH level. An AI, letrozole (Femara, 5 mg/day; Novartis, Suffern, NY, USA), was used concomitantly with recombinant FSH until the day of triggering, and then continued again for a week after oocyte retrieval. GnRH antagonist (Cetrorelix, 0.25 mg; Serono) was added to prevent premature ovulation when the lead follicle reached a mean diameter of 14 mm. When at least 2 follicles reached a mean diameter of 18 mm, the final oocyte maturation was achieved with recombinant human chorionic gonadotropin (hcg; Ovidrel, 250 or 500 μg; Serono). Oocyte retrieval was performed 36 hours after hcg triggering, using a transvaginal ultrasound guidance. Oocyte maturity was evaluated by microscopic examination and graded as mature (metaphase II), intermature (metaphase I), and immature. Mature oocytes and in vitro-matured oocytes were 243
3 Vol. 61, No. 2, 2018 cryopreserved. For embryo banking, intracytoplasmic sperm injection (ICSI) was performed using ejaculated sperm. None of the male partners had subfertile sperm parameters. Fertilization was assessed 16 to 18 hours after ICSI via the presence of 2 pronuclei and a second polar body. The quality of embryos was evaluated in accordance with the morphological criteria based on the fragmentation degree and the regularity of blastomeres on the third day after fertilization. All embryos were cryopreserved on the third day. 4. Statistical analysis Data was analyzed using R software version (R Foundation, Vienna, Austria; and compared by Mann-Whitney U, Kruskal-Wallis, or Fisher s exact tests, as indicated. Descriptive data is expressed as the median and range. The result was considered significant when the P- value was less than Results During the study interval, oocyte retrievals were performed for 37 breast cancer patients. EOR was 50.4±75.0 pg/ml, and EMOR was 65.6±41.9 pg/ml. To include only the data from patients who had normal ovarian response, patients with POR (n=2) and PCOS (n=3) were excluded from analysis. The mean age of participants was 33.2±4.8 years. Oocyte and embryo cryopreservation were performed in 21 and 8 cycles, respectively. As expected, patients who were administered with a letrozole-combined regimen, the peak serum E2 was maintained at a low level (386.3±346.9 pg/ml). The levels of serum E2 were positively correlated with the total number of oocytes retrieved (r=0.34; P=0.06) and mature oocytes retrieved (r=0.49; P=0.01). EOR was 52.4±78.8 pg/ml, and EMOR was 71.0±41.2 pg/ml. As shown in Table 1, patients were dived into 2 groups by age (age <35 vs. age 35). According to this categorization, there was no significant difference in basal characteristics or stimulation parameters. EOR was 34.5 ( ) and 40.7 ( ), respectively; EMOR was 79.8 ( ) and 68.8 ( ), respectively. There was no significant difference in the COS outcomes. Table 2 compares the baseline characteristics, stimulation parameters, and outcomes according to the starting phase of ovarian stimulation. Ovarian stimulation was started in the early follicular (n=18), late follicular (n=4), and luteal phases (n=10). There were no significant differences with respect to Table 1. Basal characteristics of the patients and in vitro fertilization outcomes according to patients' age Characteristics Age <35 (n=19) Age 35 (n=13) Total (n=32) P-value Woman's age (yr) 31.0 ( ) 38.0 ( ) 34.0 ( ) <0.001 BMI (kg/m 2 ) 22.2 ( ) 21.1 ( ) 21.8 ( ) NS Basal serum FSH (miu/ml) 4.8 ( ) 4.7 ( ) 4.8 ( ) NS Basal serum AMH (ng/ml) 3.0 ( ) 3.6 ( ) 3.3 ( ) NS Total FSH administered (IU) 2,025.0 (1, ,362.5) 1,800.0 (1, ,400.0) 1,987.5 (1, ,437.5) NS Total stimulation days 9.0 ( ) 8.0 ( ) 9.0 ( ) NS E2 on day of trigger (pg/ml) ( ) ( ) ( ) NS No. of oocytes retrieved 10.0 ( ) 8.0 ( ) 9.0 ( ) NS No. of mature oocytes retrieved 4.0 ( ) 4.0 ( ) 4.0 ( ) NS EOR 34.5 ( ) 40.7 ( ) 35.7 ( ) NS EMOR 79.8 ( ) 68.8 ( ) 70.5 ( ) NS N o. of mature oocytes cryopreserved (n=21) 4.5 ( ) 5.0 ( ) 5.0 ( ) NS No. of embryos cryopreserved (n=8) 8.0 ( ) 4.5 ( ) 5.0 ( ) NS Data are presented as median (interquartile range). Data are compared by Kruskal Wallis analysis. BMI, body mass index; FSH, follicle-stimulating hormone; AMH, anti-mullerian hormone; E2, estradiol; EOR, estradiol-oocyte ratio; EMOR, estradiol-mature oocyte ratio; NS, not significant. 244
4 Yoo Jin Shim, et al. The serum estradiol/oocyte ratio Table 2. Basal characteristics of the patients and in vitro fertilization outcomes according to starting phase Characteristics Early follicular phase (n=18) Late follicular phase (n=4) Luteal phase (n=10) Woman's age (yr) 33.5 ( ) 35.0 ( ) 34.5 ( ) NS BMI (kg/m 2 ) 21.8 ( ) 21.1 ( ) 22.5 ( ) NS Basal serum FSH (miu/ml) 4.9 ( ) 5.0 ( ) 3.6 ( ) NS Basal serum AMH (ng/ml) 2.7 ( ) 2.9 ( ) 3.5 ( ) NS P-value Total FSH administered (IU) 1,687.5 (1, ,025.0) a) 2,250.0 (1, ,775.0) b) 2,250.0 (2, ,700.0) b) Total stimulation days 7.5 ( ) 9.0 ( ) 9.5 ( ) E2 on day of trigger (pg/ml) ( ) a) ( ) b) ( ) b) NS No. of oocytes retrieved 10.0 ( ) 8.5 ( ) 7.0 ( ) NS No. of mature oocytes retrieved 4.0 ( ) 3.5 ( ) 5.0 ( ) NS EOR 38.2 ( ) 19.3 ( ) 36.0 ( ) NS EMOR 82.0 ( ) 69.0 ( ) 57.5 ( ) NS N o. of mature oocytes cryopreserved (n=21) N o. of embryos cryopreserved (n=8) 5.0 ( ) 10.0 ( ) 4.0 ( ) NS 7.0 ( ) 2.5 ( ) 6.0 ( ) NS Data are presented as median (interquartile range). Data are compared by Kruskal Wallis analysis. BMI, body mass index; FSH, follicle-stimulating hormone; AMH, anti-mullerian hormone; E2, estradiol; EOR, estradiol-oocyte ratio; EMOR, estradiol-mature oocyte ratio; NS, not significant. a,b) Different superscript means a statistical significance within the same row. age, body mass index, basal serum FSH, and AMH levels. The total gonadotropin dose was significantly higher in the late follicular and luteal phase start cycles than in early follicular phase start cycles owing to a longer stimulation. The number of total and mature oocytes retrieved and the oocyte maturity rates were similar irrespective of the start phase of ovarian stimulation. There were also no significant differences in EOR and EMOR among the groups. Discussion Our study is the first study to analyze EOR in breast cancer patients undergoing IVF for fertility preservation with a cotreatment of letrozole. The present study indicated that the levels of serum E2 were positively correlated with the total number of oocytes retrieved and mature oocytes retrieved. We showed that the EOR in these patients was 52.4±78.8 pg/ml, which was significantly lower than that during the conventional COS cycles. By using the result of this study, E2 level can be used to assess the response to the ovarian stimulation and predict the number of oocytes retrieved in advance of the oocyte pickup in breast cancer patients. The number of retrieved mature oocytes is more closely related to the IVF outcomes than the total number of retrieved oocytes. Therefore, EMOR can provide additional information compared with EOR. Again, our study is the first study to analyze EMOR in breast cancer patients undergoing IVF for fertility preservation, with a co-treatment of letrozole. The median value of EMOR was 71.0±41.2 pg/ml in these patients, which was about 1.35 times higher than that of EOR. Although the total peak serum E2 level does not have a positive or negative effect on IVF outcomes, EOR and EMOR showed to have an impact on the clinical pregnancy rate. Loumaye et al. [5] first found that EOR may be a reliable indicator for the success of IVF. According to a previous study [6], evaluating the data from over 9,000 IVF cycles, the group with an EOR between 250 and 750 showed a clinically significant increase in the clinical pregnancy rate compared with the group that had an EOR of over 1,500 (odds ratio, 3.4; 95% confidence interval, ). They concluded that EOR can be a good predictor of reproductive outcomes. Hence, we 245
5 Vol. 61, No. 2, 2018 can assert that EOR and EMOR can be used as predictive factors for reproductive outcomes. As such, a study that analyzes EOR and EMOR may be important. A future study of pregnancy trial using oocyte cryopreservation or embryo cryopreservation could reveal a correlation between EOR, EMOR, and clinical pregnancy rate in breast cancer patients undergoing IVF for fertility preservation with a co-treatment of letrozole. Further studies are necessary to better enable clinicians to predict IVF outcome by measuring EOR and EMOR in breast cancer patients for the conventional COS groups. The limitation of this research is that the relation between EOR, EMOR in breast cancer patients and reproductive outcome was not be proved. In the future, if the number of patients attempting to conceive using frozen oocytes increases, the correlation with the pregnancy rate will be analyzed. We hope to set a good precedent for many upcoming papers. Another limitation is that the number of patients analyzed is relatively small. Our academic community needs forwardlooking studies, including a larger number of patients in the future. In conclusion, measuring the peak E2 concentration in breast cancer patients undergoing IVF for fertility preservation with a co-treatment of letrozole allows for the prediction of the numbers of oocytes and mature oocytes. Acknowledgements This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. NRF-2017R1C1B ). Conflict of Interest No potential conflict of interest relevant to this article was reported. References 1. Orvieto R, Hod E, Volodarsky M, Homburg R, Rabinson J, Meltcer S. Controlled ovarian hyperstimulation: are we monitoring the appropriate sex-steroid hormones? Fertil Steril 2008;89: Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006;91: Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008;26: Kim JH, Kim SK, Lee HJ, Lee JR, Jee BC, Suh CS, et al. Efficacy of random-start controlled ovarian stimulation in cancer patients. J Korean Med Sci 2015;30: Loumaye E, Engrand P, Howles CM, O'Dea L. Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome. Fertil Steril 1997;67: Vaughan DA, Harrity C, Sills ES, Mocanu EV. Serum estradiol:oocyte ratio as a predictor of reproductive outcome: an analysis of data from >9000 IVF cycles in the Republic of Ireland. J Assist Reprod Genet 2016;33:
Efficacy of Random-start Controlled Ovarian Stimulation in Cancer Patients
ORIGINAL ARTICLE Obstetrics & Gynecology http://dx.doi.org/10.3346/jkms.2015.30.3.290 J Korean Med Sci 2015; 30: 290-295 Efficacy of Random-start Controlled Ovarian Stimulation in Cancer Patients Jee Hyun
More informationHana Park, Chung-Hoon Kim, Eun-Young Kim, Jei-Won Moon, Sung-Hoon Kim, Hee-Dong Chae, Byung-Moon Kang
Original Article Obstet Gynecol Sci 2015;58(6):481-486 http://dx.doi.org/10.5468/ogs.2015.58.6.481 pissn 2287-8572 eissn 2287-8580 Effect of second-line surgery on in vitro fertilization outcome in infertile
More informationOriginal Article. Introduction
Original Article Obstet Gynecol Sci 2017;60(1):63-68 https://doi.org/10.5468/ogs.2017.60.1.63 pissn 2287-8572 eissn 2287-8580 In vitro fertilization outcomes in women with surgery induced diminished ovarian
More informationFactors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2015;42(2):67-71 Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles Ju Hee Park
More informationAnti-Müllerian Hormone Levels in the Follicular Fluid of the Preovulatory Follicle: A Predictor for Oocyte Fertilization and Quality of Embryo
ORIGINAL ARTICLE Obstetrics & Gynecology http://dx.doi.org/1.3346/jkms.214.29.9.1266 J Korean Med Sci 214; 29: 1266-127 Anti-Müllerian Hormone Levels in the Follicular Fluid of the Preovulatory Follicle:
More informationIn Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome
Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,
More informationCase Report. Introduction. Seul Ki Kim 1,2*, Myo Sun Kim 1*, Hoon Kim 2, Sun Mie Kim 2,3, Jung Ryeol Lee 1,2, Chang Suk Suh 1,2, Seok Hyun Kim 2
Case Report Obstet Gynecol Sci 2015;58(6):537-541 http://dx.doi.org/10.5468/ogs.2015.58.6.537 pissn 2287-8572 eissn 2287-8580 Mature oocyte retrieval during laparotomic debulking surgery following random-start
More informationThe effect of luteal phase progesterone supplementation on natural frozen-thawed embryo transfer cycles
Original Article Obstet Gynecol Sci 2014;57(4):291-296 http://dx.doi.org/10.5468/ogs.2014.57.4.291 pissn 2287-8572 eissn 2287-8580 The effect of luteal phase progesterone supplementation on natural frozen-thawed
More informationEvaluation of ovarian response prediction according to age and serum AMH levels in IVF cycles: a retrospective analysis
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Pillai SM et al. Int J Reprod Contracept Obstet Gynecol. 2017 Aug;6(8):3306-3310 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20173190
More informationOriginal Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and embryo transfer
Int J Clin Exp Med 2015;8(7):11327-11331 www.ijcem.com /ISSN:1940-5901/IJCEM0008838 Original Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and
More informationOvarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase
Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase Michael von Wolff, M.D., a Christian J. Thaler, M.D., b Torsten Frambach, M.D., c Cosima Zeeb,
More informationNeil Goodman, MD, FACE
Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects
More informationIvf day 6 estradiol level
Ivf day 6 estradiol level Search It is also important to measure the estradiol on day 3. Day 2 is fine. The reason its day 3 is 15-20 years ago, the IVF medications were always started on day 3. Day 3
More informationLOW RESPONDERS. Poor Ovarian Response, Por
LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients
More informationPrognosticating ovarian reserve by the new ovarian response prediction index
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Tak A et al. Int J Reprod Contracept Obstet Gynecol. 2018 Mar;7(3):1196-1200 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20180917
More informationLuteal phase rescue after GnRHa triggering Progesterone and Estradiol
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective
More informationAnti-Mullerian hormone (AMH) as predictor of ovarian reserve
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Shembekar CA et al. Int J Reprod Contracept Obstet Gynecol. 2017 Sep;6(9):4006-4010 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20174053
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,
More informationInterpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used
Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Ellenbogen A., M.D., Shalom-Paz E., M.D, Asalih N., M.D, Samara
More informationPrinciples of Ovarian Stimulation
Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle
More informationlbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour
lbt lab tests t and Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour Research Instituteof Avicenna 4/23/2012 Why good prediction of poor response good prediction i of OHSS application appropriate
More informationIVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
More informationNomogram to predict the number of oocytes retrieved in controlled ovarian stimulation
ORIGINAL ARTICLE http://dx.doi.org/.63/cerm.216.43.2.112 pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 216;43(2):112-118 Nomogram to predict the number of oocytes retrieved in controlled ovarian
More informationCOMPARING AMH, AFC AND FSH FOR PREDICTING HIGH OVARIAN RESPONSE IN WOMEN UNDERGOING ANTAGONIST PROTOCOL
COMPARING AMH, AFC AND FSH FOR PREDICTING HIGH OVARIAN RESPONSE IN WOMEN UNDERGOING ANTAGONIST PROTOCOL Nguyen Xuan Hoi1, Nguyen Manh Ha2 1 National Obstetrics and Gynecology Hospital, 2Hanoi Medical Unviversity
More informationInfertility Clinical Guideline
Infertility Clinical Guideline Ovarian Stimulation Guideline Purpose: To provide sufficient background regarding various ovarian stimulation protocols for In Vitro Fertilization cycles. Goal: To assist
More informationClinical outcomes of frozen embryo transfer cycles after freeze-all policy to prevent ovarian hyperstimulation syndrome
Original Article Obstet Gynecol Sci 2018;61(4):497-504 https://doi.org/10.5468/ogs.2018.61.4.497 pissn 2287-8572 eissn 2287-8580 Clinical outcomes of frozen embryo transfer cycles after freeze-all policy
More informationEmbryonic development in human oocytes fertilized by split insemination
Original Article Obstet Gynecol Sci 2015;58(3):217-222 http://dx.doi.org/10.5468/ogs.2015.58.3.217 pissn 2287-8572 eissn 2287-8580 Embryonic development in human oocytes fertilized by split insemination
More informationFertility Preservation for Breast Cancer. Elizabeth S. Ginsburg MD Medical Director, ART Program Brigham & Women s Hospital
Fertility Preservation for Breast Cancer Elizabeth S. Ginsburg MD Medical Director, ART Program Brigham & Women s Hospital Learning Objectives To be able to list and describe processes of ovulation induction
More informationSoluble Human Leukocyte Antigen G Level in Fluid from Single Dominant Follicle and the Association with Oocyte Competence
Original Article http://dx.doi.org/10.3349/ymj.2011.52.6.967 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 52(6):967-971, 2011 Soluble Human Leukocyte Antigen G Level in Fluid from Single Dominant Follicle
More informationClinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
International Reproductive Medicine Volume 2013, Article ID 135258, 4 pages http://dx.doi.org/10.1155/2013/135258 Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin
More informationFERTILITY PRESERVATION IN BREAST CANCER PATIENTS: FOLLICULAR BIOMARKERS IN LETROZOLE ASSOCIATED OVARIAN HYPERSTIMULATION
FERTILITY PRESERVATION IN BREAST CANCER PATIENTS: FOLLICULAR BIOMARKERS IN LETROZOLE ASSOCIATED OVARIAN HYPERSTIMULATION Ornit GOLDRAT Research Laboratory in Human Reproduction, Fertility Clinic, Department
More informationStimulated intrauterine insemination in women with unilateral tubal occlusion
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2012;39(2):68-72 Stimulated intrauterine insemination in women with unilateral tubal occlusion Gwang Yi 1, Byung Chul Jee 1-3, Chang
More informationTreatment of Poor Responders
Treatment of Poor Responders Pathophysiology of Poor Responders Deficiency in systemic IGF 1 levels (Bahceci, 2007) Lower intra ovarian T levels Reduced FSH receptor expression (Cai, 2007) Bahceci, 2007,
More informationUse of in vitro maturation for fertility preservation
Use of in vitro maturation for fertility preservation G. Arroyo Servei de Medicina de la Reproducció Departament d Obstetrícia, Ginecologia i Reproducció INSTITUT UNIVERSITARI DEXEUS MEDICAL STRATEGY TO
More informationAge specific serum anti-müllerian hormone levels in 1,298 Korean women with regular menstruation
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2011;38(2):93-97 Age specific serum anti-müllerian hormone levels in 1,298 Korean women with regular menstruation Ji Hee Yoo, Hye Ok
More informationA Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist
1 *, ** * * * ** A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist Yoon Sung Nam, Nam Keun Kim*, Eun Kyung Kim**, Hyung Min Chung** and Kwang
More informationThe effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study
Clinical research The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Ashraf Moini 1,2, Shahrzad Zadeh Modarress 3, Elham Amirchaghmaghi
More informationMelanoma-What Every Woman Need to Know about Fertility and Pregnancy
Melanoma-What Every Woman Need to Know about Fertility and Pregnancy Women diagnosed with melanoma may require counseling for fertility preservation, fertility treatment and safety of pregnancy after treatment.
More informationFemale Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
More informationLH activity administration during the
LH activity administration during the luteal-follicular transition Richard Fleming On behalf of the Luveris Pre-treatment group University of Glasgow Scotland Androgens have a Paracrine action in the Early
More informationSample size a Main finding b Main limitations
1 Table 1. Available studies on the relation between endometriosis and miscarriage (1995-2015). Study (citation) Country Study period Study design Sample size a Main finding b Main limitations Matoras
More informationDoes triggering ovulation by 5000 IU of uhcg affect ICSI outcome? *
Middle East Fertility Society Journal Vol. 11, No. 2, 2006 Copyright Middle East Fertility Society Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Amany A.M. Shaltout, M.D. Mohamed
More informationOvarian response in three consecutive in vitro fertilization cycles
FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Ovarian response in
More informationEstradiol Level on Day 2 and Day of Trigger: A Potential Predictor of the IVF-ET Success
DOI 10.1007/s13224-014-0515-6 ORIGINAL ARTICLE Estradiol Level on Day 2 and Day of Trigger: A Potential Predictor of the IVF-ET Success Prasad Sudha Kumar Yogesh Singhal Megha Sharma Shashi Received: 27
More informationI. ART PROCEDURES. A. In Vitro Fertilization (IVF)
DFW Fertility Associates ASSISTED REPRODUCTIVE TECHNOLOGY (ART) Welcome to DFW Fertility Associates/ Presbyterian-Harris Methodist Hospital ARTS program. This document provides an overview of treatment
More informationBest practices of ASRM and ESHRE
Best practices of ASRM and ESHRE Late submission Cortina d Ampezzo, Italy 1-3 March 2012 A joint meeting between the American Society for Reproductive Medicine and the European Society of Human Reproduction
More informationDoes previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?
J Assist Reprod Genet (26) 23:427 431 DOI 1.17/s1815-6-965-x ASSISTED REPRODUCTION Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation
More informationClinical Study Comparison of IVF Outcomes between Minimal Stimulation and High-Dose Stimulation for Patients with Poor Ovarian Reserve
Hindawi Publishing Corporation International Journal of Reproductive Medicine Volume 2014, Article ID 581451, 5 pages http://dx.doi.org/10.1155/2014/581451 Clinical Study Comparison of IVF Outcomes between
More informationUse of clomiphene to prevent premature luteinizing hormone surge during controlled ovarian hyper stimulation
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Bhandari S et al. Int J Reprod Contracept Obstet Gynecol. 2016 Jun;5(6):1944-1948 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationReproductive BioMedicine Online (2010) 20, 634 638 www.sciencedirect.com www.rbmonline.com ARTICLE In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing
More informationThe emergence of Personalized Medicine protocols for IVF.
Individualising IVF: Introduction to the POSEIDON Concept Introduction The emergence of Personalized Medicine protocols for IVF. Differences between patients: age, ovarian reserve, BMI or presence of ovarian
More informationCessation of gonadotropin-releasing hormone antagonist on triggering day in flexible multipledose protocol: A randomized controlled study
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2013;40(2):83-89 Cessation of gonadotropin-releasing hormone antagonist on triggering day in flexible multipledose protocol: A randomized
More informationINDICATIONS OF IVF/ICSI
PROCESS OF IVF/ICSI INDICATIONS OF IVF/ICSI IVF is most clearly indicated when infertility results from one or more causes having no other effective treatment; Tubal disease. In women with blocked fallopian
More informationJMSCR Vol 06 Issue 09 Page September 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i9.53 Role of Anti-Mullerian Hormone
More informationDr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain. Declared no potential conflict of interest
Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain Declared no potential conflict of interest Is there a role for LH in elderly patients? Dr. Ernesto Bosch Instituto Valenciano de Infertilidad.
More informationPremature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles
Arch Gynecol Obstet (2010) 281:747 752 DOI 10.1007/s00404-009-1248-0 REPRODUCTIVE MEDICINE Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles Esra
More informationUtility of Estradiol as a Predictive Marker of Ovarian Hyper Stimulation Syndrome
Research Article imedpub Journals http://www.imedpub.com/ Annals of Clinical and Laboratory Research DOI: 10.21767/2386-5180.1000167 Utility of Estradiol as a Predictive Marker of Ovarian Hyper Stimulation
More informationMenstrual characteristics in Korean women with endometriosis: a pilot study
Original Article Obstet Gynecol Sci 2018;61(1):142-146 https://doi.org/10.5468/ogs.2018.61.1.142 pissn 2287-8572 eissn 2287-8580 Menstrual characteristics in Korean women with endometriosis: a pilot study
More informationThe Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (4), Page
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (4), Page 858-866 Comparative study between fixed and flexible GnRH antagonist protocol versus GnRH agonist long protocol in polycystic
More informationFemale Reproductive System. Lesson 10
Female Reproductive System Lesson 10 Learning Goals 1. What are the five hormones involved in the female reproductive system? 2. Understand the four phases of the menstrual cycle. Human Reproductive System
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 September 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 September 2010 100 µg/0.5 ml, solution for injection B/1 prefilled syringe + 1 needle (CIP code: 374 590-1) 150
More informationInfluence ovarian stimulation on oocyte and embryo quality. Prof.Dr. Bart CJM Fauser
Influence ovarian stimulation on oocyte and embryo quality Prof.Dr. Bart CJM Fauser How to balance too much vs too little? Lecture Outline Context ovarian stimulation Impact ovarian stimulation on oocyte
More information(BMI)=18.0~24.9 kg/m 2 ;
33 10 Vol.33 No.10 2013 10 Oct. 2013 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2013.10.0672 E-mail: randc_journal@163.com - ( 400013) : () GnRH-a - () : IVF- ET 233 A (I~II 102 ) B (III~IV
More informationin vitro fertilization
FERTILITY AND STERILITY VOL 69, NO. 6, JUNE 1998 Copyright (#1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Elevated levels of basal
More informationFollicle-stimulating hormone/luteinizing hormone ratio as an independent predictor of response to controlled ovarian stimulation
Follicle-stimulating hormone/luteinizing hormone ratio as an independent predictor of response to controlled ovarian stimulation Aim: To determine whether a follicle-stimulating hormone (FSH)/luteinizing
More informationUnderstanding Infertility, Evaluations, and Treatment Options
Understanding Infertility, Evaluations, and Treatment Options Arlene J. Morales, M.D., F.A.C.O.G. Fertility Specialists Medical Group, Inc. What We Will Cover Introduction What is infertility? Briefly
More informationAntral follicle count as a predictor of ovarian response
Original article Antral follicle count as a predictor of ovarian response N. Lonegro a, N. Napoli a,*, R. Pesce b and C. Chacón a a Imaging Department, Hospital Italiano de Buenos Aires, Ciudad Autónoma
More informationIVM in PCOS patients. Introduction (1) Introduction (2) Michael Grynberg René Frydman
IVM in PCOS patients Michael Grynberg René Frydman Department of Obstetrics and Gynecology A. Beclere Hospital, Clamart, France Maribor, Slovenia, 27-28 February 2009 Introduction (1) IVM could be a major
More informationGonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series
Original Article Obstet Gynecol Sci 2017;60(5):449-454 https://doi.org/10.5468/ogs.2017.60.5.449 pissn 2287-8572 eissn 2287-8580 Gonadotropin releasing hormone antagonist administration for treatment of
More informationElena H. Yanushpolsky, M.D., a Shelley Hurwitz, Ph.D., b Eugene Tikh, B.S., c and Catherine Racowsky, Ph.D. a
FERTILITY AND STERILITY VOL. 80, NO. 1, JULY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Predictive usefulness of cycle
More informationVanessa N. Weitzman, M.D., Lawrence Engmann, M.D., Andrea DiLuigi, M.D., Donald Maier, M.D., John Nulsen, M.D., and Claudio Benadiva, M.D.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol
More informationOriginal Article. Fauzia HaqNawaz 1*, Saadia Virk 2, Tasleem Qadir 3, Saadia Imam 3, Javed Rizvi 2
Original Article Comparison of Letrozole and Clomiphene Citrate Efficacy along with Gonadotrophins in Controlled Ovarian Hyperstimulation for Intrauterine Insemination Cycles Fauzia HaqNawaz 1*, Saadia
More informationInternational Journal of Women s Health and Reproduction Sciences Vol. 6, No. 2, April 2018, ISSN
http://www.ijwhr.net Open Access doi 10.15296/ijwhr.2018.31 Original Article International Journal of Women s Health and Reproduction Sciences Vol. 6, No. 2, April 2018, 187 191 ISSN 2330-4456 Comparison
More informationOvarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy
Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy M.E. Coccia, F. Cammilli, L. Ginocchini, F. Borruto* and F. Rizzello Dept Gynaecology Perinatology and Human
More informationPrognostic factors of ovarian response and IVF outcome in patients with deep infiltrating endometriosis Claire GAUCHE-CAZALIS, Chadi YAZBECK
Prognostic factors of ovarian response and IVF outcome in patients with deep infiltrating endometriosis Claire GAUCHE-CAZALIS, Chadi YAZBECK Obstetrics Gynecology and Reproductive Medicine Department Bichat
More informationHonorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive FIGO s Distinguished Merit Award for Services towards women s health.
Prof.Duru Shah Founder President The PCOS Society (India) President Elect of the Indian Society for Assisted Reproduction (ISAR) Honorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive
More informationPre-implantation genetic diagnosis and pre-implantation genetic screening: two years experience at a single center
Original Article Obstet Gynecol Sci 2018;61(1):95-101 https://doi.org/10.5468/ogs.2018.61.1.95 pissn 2287-8572 eissn 2287-8580 Pre-implantation genetic diagnosis and pre-implantation genetic screening:
More informationUtility of color Doppler indices of dominant follicular
Ultrasound Obstet Gynecol 2002; 20: 592 596 Utility of color Doppler indices of dominant follicular Blackwell Science, Ltd blood flow for prediction of clinical factors in in vitro fertilization-embryo
More informationArticle Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment
RBMOnline - Vol 7. No 2. 185 189 Reproductive BioMedicine Online; www.rbmonline.com/article/900 on web 18 June 2003 Article Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix,
More informationA comparative study between agonist and antagonist protocol for ovarian stimulation in art cycles at a rural set up in South Gujarat
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Nadkarni PK et al. Int J Reprod Contracept Obstet Gynecol. 2015 Jun;4(3):617-621 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationIs it the seed or the soil? Arthur Leader, MD, FRCSC
The Physiological Limits of Ovarian Stimulation Is it the seed or the soil? Arthur Leader, MD, FRCSC Objectives 1. To consider how ovarian stimulation protocols work in IVF 2. To review the key events
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Kasum M., Kurdija K., Orešković S., Čehić E., Pavičić-Baldani D., Škrgatić L. (2016) Combined ovulation triggering with GnRH agonist and hcg in IVF patients. Gynecological
More informationFixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol
Yamanashi Med. J. 14(3), 77 ~ 82, 1999 Original Article Fixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol Tsuyoshi KASAI and Kazuhiko
More informationFertility care for women diagnosed with cancer
Saint Mary s Hospital Department of Reproductive Medicine Information for Patients Fertility care for women diagnosed with cancer Contents Page Overview... 2 Our service... 2 Effects of cancer treatment
More informationResearch Article. Jayakrishnan Krishnakumar 1, Akansha Agarwal 1, Divya Nambiar 1, Shankar Radhakrishnan 2 *
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Krishnakumar J et al. Int J Reprod Contracept Obstet Gynecol. 2016 Aug;5(8):2762-2767 www.ijrcog.org pissn 2320-1770 eissn
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Kasum M., Šimunić V., Orešković S., Beketić-Orešković L. (2014) Fertility preservation with ovarian stimulation protocols prior to cancer treatment. Gynecological Endocrinology,
More informationMilder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization
Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization Revelli et al. Reproductive Biology and Endocrinology 2011, 9:25 Presenter: R2 孫怡虹 Background
More informationEndometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot study
Reproductive BioMedicine Online (2010) 21, 50 55 www.sciencedirect.com www.rbmonline.com ARTICLE Endometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot
More informationORIGINAL ARTICLE. Introduction. Hyo Young Park 1, Min Young Lee 2, Hyo Young Jeong 2, Yong Sook Rho 2, Sang Jin Song 1, Bum-Chae Choi 2
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2015;42(2):62-66 Efficacy of corifollitropin alfa followed by recombinant follicle-stimulating hormone in a gonadotropinreleasing hormone
More information(1.,, ) (2.,,, )
33 11 Vol.33 No.11 2013 11 Nov. 2013 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2013.11.0749 E-mail: randc_journal@163.com IVF-ET 1 2 1 1 1 1 1 (1. 510150) (2. 510150) : (COH) (premature
More informationLan Wang, Yiqing Zhao, Xiyuan Dong, Kai Huang, Rui Wang, Licheng Ji, Ya Wang, Hanwang Zhang
Int J Clin Exp Med 2015;8(2):2711-2718 www.ijcem.com /ISSN:1940-5901/IJCEM0003568 Original Article Could pretreatment with oral contraceptives before pituitary down regulation reduce the incidence of ovarian
More informationInfertility in Women over 35. Alison Jacoby, MD Dept. of Ob/Gyn UCSF
Infertility in Women over 35 Alison Jacoby, MD Dept. of Ob/Gyn UCSF Learning Objectives Review the effect of age on fertility Fertility counseling for the patient >35 - timing - lifestyle - workup Fertility
More informationMedicine. Wei Yang, MMed, Tao Zhang, MMed, Zhou Li, PhD, Xinling Ren, PhD, Bo Huang, PhD, Guijin Zhu, MMed, Lei Jin, PhD. Observational Study
Observational Study Medicine Combined analysis of endometrial thickness and pattern in predicting clinical outcomes of frozen embryo transfer cycles with morphological good-quality blastocyst A retrospective
More informationResponses to fertility treatment among patients with cancer: a retrospective cohort study
Dolinko et al. Fertility Research and Practice (2018) 4:3 https://doi.org/10.1186/s40738-018-0048-2 RESEARCH ARTICLE Open Access Responses to fertility treatment among patients with cancer: a retrospective
More informationHongjuan Ye 1*, Hui Tian 1, Wen He 2, Qifeng Lyu 2, Yanping Kuang 2, Qiuju Chen 2* and Lihua Sun 1*
Ye et al. Reproductive Biology and Endocrinology (2018) 16:53 https://doi.org/10.1186/s12958-018-0373-7 RESEARCH Open Access Progestin-primed milder stimulation with clomiphene citrate yields fewer oocytes
More informationART Drugs. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.02 Subject: ART Drugs Page: 1 of 7 Last Review Date: September 15, 2017 ART Drugs Description Bravelle
More informationAgonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic
More information2013 Sep.; 24(3):
Journal of Reproduction & Contraception doi: 10.7669/j.issn.1001-7844.2013.03.0151 2013 Sep.; 24(3):151-158 E-mail: randc_journal@163.com Reducing the Trigger Dose of Human Chorionic Gonadotrophin Does
More informationPredictors of live birth and pregnancy success after in vitro fertilization in infertile women aged 40 and over
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 217;44(2):111-117 Predictors of live birth and pregnancy success after in vitro fertilization in infertile women aged 4 and over Hye
More information